Tri Locum Partners LP
CIK 0001826434 · NEW YORK, NY · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$813.2M
2026 Q2
Positions
19
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
80.0%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
JNJ
JOHNSON & JOHNSON
13.3%
VRTX
VERTEX PHARMACEUTICALS INC
12.3%
LLY
ELI LILLY & CO
11.3%
ASND
ASCENDIS PHARMA A/S
8.5%
DXCM
DEXCOM INC
6.8%
AXSM
AXSOME THERAPEUTICS INC.
6.6%
JAZZ
JAZZ PHARMACEUTICALS PLC
6.6%
ELVN
ENLIVEN THERAPEUTICS INC
5.4%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.